1-4 of 4
Erika M. Moseson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Investigation of the Biological Differences between Bcr-Abl Kinase Mutations Resistant to Imatinib.

Ian J. Griswold, PhD, Thomas Bumm, MD, Thomas O’Hare, PhD, Erika M. Moseson, Brian J. Druker, MD, Michael W. Deininger, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 555.
https://doi.org/10.1182/blood.V104.11.555.555
Published: 2004
Journal Articles

Glutathione-Depletion Potently Enhances the Cytotoxic Activity of Arsenic Trioxide in Imatinib Sensitive and Resistant Bcr-Abl Positive Cell Lines.

Heiko Koenig, MD, Erika M. Moseson, MA, Christian Lorentz, MD, Peter Paschka, MD, Junia V. Melo, MD, PhD, Ruediger Hehlmann, MD, Andreas Hochhaus, MD, Paul La Rosée, MD
Journal: Blood
Blood (2004) 104 (11): 2098.
https://doi.org/10.1182/blood.V104.11.2098.2098
Published: 2004
Journal Articles

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML

Thomas O'Hare, Roy Pollock, Eric P. Stoffregen, Jeffrey A. Keats, Omar M. Abdullah, Erika M. Moseson, Victor M. Rivera, Hao Tang, Chester A. Metcalf, III, Regine S. Bohacek, Yihan Wang, Raji Sundaramoorthi, William C. Shakespeare, David Dalgarno, Tim Clackson, Tomi K. Sawyer, Michael W. Deininger, Brian J. Druker
Journal: Blood
Blood (2004) 104 (8): 2532–2539.
https://doi.org/10.1182/blood-2004-05-1851
Published: 2004
Journal Articles

In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl–positive cell lines

Paul La Rosée, Kara Johnson, Amie S. Corbin, Eric P. Stoffregen, Erika M. Moseson, Stephanie Willis, Michael M. Mauro, Junia V. Melo, Michael W. Deininger, Brian J. Druker
Journal: Blood
Blood (2004) 103 (1): 208–215.
https://doi.org/10.1182/blood-2003-04-1074
Published: 2004